文献速递慢性肾脏病遗传性与小管间质肾病

ADPKD肾脏体积增长率变化的估算方法

Estimation of Changes in Kidney Volume Growth Rate in ADPKD.
PubMed 文献 · Kidney Int Rep · 2020-06-20

本研究基于TEMPO 3:4试验中453例安慰剂组受试者,评估Mayo影像分类中估测的HtTKV斜率(eHTKV-α)的稳定性,并探索参数A和K的优化取值。结果显示A=0、K=130时eHTKV-α在随访期间接近稳定,且托伐普坦治疗组eHTKV-α显著低于基线,提示可通过eHTKV-α变化估算治疗对HtTKV斜率的影响。

要点

  • eHTKV-α(A=0,K=130)在标准治疗成人ADPKD患者中随访期间接近稳定。
  • 托伐普坦治疗3年内eHTKV-α显著低于基线,可据此估算治疗对HtTKV斜率的影响。
  • Mayo影像分类原参数K=150时eHTKV-α第三年较基线显著变化,K=130更稳定。

核心结论

  • 采用A=0和K=130计算的eHTKV-α在标准治疗成人ADPKD患者中从基线至随访接近稳定,治疗对HtTKV斜率的影响可通过eHTKV-α相对基线的变化来估算。

研究设计与样本

  • 基于TEMPO 3:4试验中453例安慰剂组受试者评估eHTKV-α的恒定性,并以杏林大学队列239例标准治疗患者作为验证。
  • 在TEMPO 3:4中809例托伐普坦治疗受试者中评估eHTKV-α相对基线的变化。

主要发现

  • 安慰剂组中,eHTKV-α(A=0,K=150)在第三年较基线显著变化。
  • 安慰剂亚组回归线在年龄0附近汇聚,故设定A=0,并得到杏林大学队列验证。
  • 选择K=130是因为eHTKV-α相对基线的变化最小。
  • 杏林大学队列验证了eHTKV-α(A=0,K=130)的恒定性,但未验证eHTKV-α(A=0,K=150)的恒定性。
  • 托伐普坦治疗组中eHTKV-α在3年内持续显著低于基线。

关键数值与推荐

  • eHTKV-α计算公式:[HtTKV at age t] = K(1+α/100)(t-A),其中设定A=0、K=130。
  • Mayo影像分类原采用K=150、A=0。

临床怎么用

  • 在ADPKD标准治疗患者中,可采用A=0、K=130计算的eHTKV-α,通过其相对基线的变化来估算治疗对HtTKV斜率的影响。

局限性

  • 验证队列来自单中心(杏林大学队列),外部推广性需进一步确认。
  • 研究基于TEMPO 3:4试验人群,结论是否适用于其他人群尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the Mayo Imaging Classification (MIC) for autosomal dominant polycystic kidney disease (ADPKD), the height-adjusted total kidney volume (HtTKV) growth rate is estimated for classification. Estimated HtTKV slope, termed as eHTKV-α, is calculated by the equation [HtTKV at age t] = K(1+α/100)(t-A), where K = 150 and A = 0 are used in MIC. If eHTKV-α is nearly stable during a standard-of-care period, the change in eHTKV-α from baseline can be used for estimation of the treatment effect on the HtTKV slope. METHODS: The constancy of eHTKV-α (A = 0 and K = 150) was evaluated using 453 placebo-assigned subjects in the Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 trial. A and K were sought out respectively by a converged pattern of regression lines of log10(HtTKV) plotted against age for subgroups divided according to MIC, and by change in eHTKV-α from baseline. A total of 239 standard-of-care patients from the Kyorin University Cohort (KUC) served as validation. Changes in eHTKV-α from baseline were evaluated in 809 tolvaptan-treated subjects in TEMPO 3:4. RESULTS: In placebo-assigned subjects, eHTKV-α (A = 0 and K = 150) changed significantly from baseline at the third year. As regression lines of placebo-assigned subgroups converged around age 0, A was set as 0, which was confirmed by KUC. K = 130 was selected because of minimal change in eHTKV-α from baseline. The KUC validated the constancy of eHTKV-α (A = 0 and K = 130) but not that of eHTKV-α (A=0 and K=150). In tolvaptan-treated subjects, eHTKV-α remained significantly lower than baseline for 3 years. CONCLUSIONS: eHTKV-α (A = 0 and K = 130) was nearly stable from baseline through follow-up in standard-of-care adults. Treatment effects on the HtTKV slope can be estimated by changes in eHTKV-α from baseline.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Higashihara E, Fukuhara H, Ouyang J, et al. Estimation of Changes in Kidney Volume Growth Rate in ADPKD. Kidney Int Rep. 2020. PMID: 32954070. doi:10.1016/j.ekir.2020.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。